TG Therapeutics to Participate in the 9th Annual Evercore Healthcare Conference

November 25, 2026

Fireside chat scheduled for Tuesday, December 1, 2026 at 10:00 AM ET

NEW YORK--(BUSINESS WIRE)--Nov. 25, 2026-- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the 9th Annual Evercore Healthcare Conference, which is taking place from November 30 - December 2, 2026. The fireside chat is scheduled to take place on Tuesday, December 1, 2026, at 10:00 AM ET.

A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company's website at http://ir.tgtherapeutics.com/events.

ABOUT TG THERAPEUTICS

TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.

BRIUMVI® is a registered trademark of TG Therapeutics, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261125453614/en/

Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4

Media Relations
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6

Source: TG Therapeutics, Inc.